| Characteristic | Placebo (N = 9) | PRO 140 | All subjects (N = 39) | ||
| 0.5 mg/kg (N = 10) | 2 mg/kg (N = 10) | 5 mg/kg (N = 10) | |||
| Age (yrs) | 40.3 (23.8 to 50.2) | 37.1 (24.1 to 53.2) | 37.6 (23.2 to 51.5) | 42.8 (22.9 to 61.1) | 40.3 (22.9 to 61.1) |
| Sex (no. male/no. female) | 8/1 | 10/0 | 8/2 | 5/5 | 31/8 |
| Race (no. black/no. white/ no. other) | 4/5/0 | 4/4/2 | 4/6/0 | 5/4/1 | 17/19/3 |
| Prior antiretroviral therapy (no.) | 3 | 6 | 3 | 3 | 15 |
| HCV seropositive (no.) | 1 | 1 | 3 | 2 | 7 |
| Weight (kg) | 81.4 (57.3 to 101.7) | 81.0 (54.2 to 111.4) | 81.7 (55.9 to 142.9) | 73.4 (52.7 to 86.8) | 80.9 (52.7 to 142.9) |
| CD4+ cell count, cells/µL | 439 (281 to 555) | 493 (443 to 762) | 438 (269 to 613) | 535 (303 to 853) | 484 (269 to 853) |
| HIV‐1 RNA level, log10 copies/mL | 4.44 (3.98 to 5.61) | 4.45 (3.79 to 5.54) | 4.44 (3.89 to 4.94) | 4.37 (3.81 to 5.36) | 4.43 (3.79 to 5.61) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.